China · Delayed Price · Currency is CNY HitGen Company Description
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally.
Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology.
The company’s product pipeline also includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; HG153 a Menin-MLL tablet; HG248; HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation; and HGP1069, a ROCK2 inhibitor eye drop.
In addition, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services.
Further, the company focuses on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases.
The company was incorporated in 2012 and is based in Chengdu, China.
| Country | China |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 483 |
| CEO | Li Jin |
Contact Details
Address: Building C2 Chengdu, 610200 China | |
| Phone | 86 28 8519 7385 |
| Website | hitgen.com |
Stock Details
| Ticker Symbol | 688222 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Li Jin | Chairman and GM |
| Dr. Hongge Liu CFA, Ph.D. | Chief Financial Officer |
| Shiwei Geng | Secretary |
| Dengfeng Dou | Deputy General Manager |
| Guansai Liu | Deputy General Manager |
| Chunyan Hu | Accounting Supervisor |
| Barry A. Morgan | Chief Scientist |